|
|
|
|
|
|
|
|
|
Sirona Biochem Announces SGLT2 Inhibitor Development Progress
|
Vancouver, BC, July 12, 2019--Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) has announced that clinical development of Sirona's SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events.
|
|
|
|
|
|